SCHEMBL4025880

SCHEMBL4025880

ClCCOCn1cnc2cccnc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
PABPC1 P11940 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
CSF1R P07333 2/20 0.37
CYP11B1 P15538 2/20 0.34
CYP11B2 P19099 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
TNF P01375 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
GRM2 Q14416 1/20 0.33
TSHR P16473 2/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022505 0.85 MEN1 (0.44) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL4028187 0.85 MEN1 (0.47) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL13870055 0.81 MEN1 (0.41) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL4022616 0.79 MEN1 (0.52) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL4020080 0.78 MEN1 (0.48) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL5015508 0.78 MEN1 (0.51) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL9862988 0.73 LMNA (0.49) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL27708062 0.72 MEN1 (0.51) MEN1TP53PABPC1KMT2ALMNA
SCHEMBL8970101 0.72 MEN1 (0.51) MEN1TP53PABPC1KMT2ACSF1R
SCHEMBL5016756 0.69 MEN1 (0.52) MEN1TP53PABPC1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524823-B2 Macrolides BASILEA PHARMACEUTICA AG (CH) 2009-04-28 US disclosed
EP-1846430-B1 NEW MACROLIDES BASILEA PHARMACEUTICA AG (CH) 2009-04-01 EP disclosed
EP-1846430-A1 NEW MACROLIDES Basilea Pharmaceutica AG (CH) 2007-10-24 EP disclosed
US-20060264387-A1 Macrolides BASILEA PHARMACEUTICA AG (CH) 2006-11-23 US disclosed
WO-2006084410-A1 NEW MACROLIDES BASILEA PHARMACEUTICA AG (CH) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264387-A1 Macrolides PPME1, MGAM, SMPD1 MEN1 1597/4885TP53 4833/4885PABPC1 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.